{{Drugbox
| verifiedrevid = 470609936
| IUPAC_name = (−)-(3''R'')-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid
| image = Tiagabine.svg
| width = 250

<!--Clinical data-->
| tradename = Gabitril
| Drugs.com = {{drugs.com|monograph|tiagabine-hydrochloride}}
| pronounce = {{IPAc-en|t|aɪ|ˈ|æ|ɡ|ə|b|iː|n}} 
| MedlinePlus = a698014
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral ([[Tablet (pharmacy)|tablets]])

<!--Pharmacokinetic data-->
| bioavailability = 90–95%<ref name="LemkeWilliams2012">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA562|date=24 January 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-60913-345-0|pages=562–}}</ref>
| protein_bound = 96%<ref name="LemkeWilliams2012" />
| metabolism = [[Liver|Hepatic]] ([[Cytochrome P450 oxidase|CYP450]] system,<ref name="LemkeWilliams2012" /> primarily [[CYP3A]])<ref name="PI">{{cite web|title=Gabitril (tiagabine hydrochloride) Tablets. U.S. Full Prescribing Information|url=http://www.gabitril.com/Gabitril_PI.pdf|publisher=Cephalon, Inc.|accessdate=8 April 2016}}</ref>
| onset = [[Cmax (pharmacology)|T<small>max</small>]] = 45 min<ref name="PI" />
| elimination_half-life = 5–8 hours<ref name="Brodie1995">{{cite journal|last1=Brodie|first1=Martin J.|title=Tiagabine Pharmacology in Profile|journal=Epilepsia|volume=36|issue=s6|year=1995|pages=S7–S9|issn=0013-9580|doi=10.1111/j.1528-1157.1995.tb06015.x|pmid=8595791}}</ref>
| excretion = [[Feces|Fecal]] (63%) and [[Kidney|renal]] (25%)<ref name="PI" />

<!--Identifiers-->
| IUPHAR_ligand = 4685
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 115103-54-3
| ATC_prefix = N03
| ATC_suffix = AG06
| PubChem = 60648
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00906
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 54661
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Z80I64HMNP
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08588
| ChEBI = 9586
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1027

<!--Chemical data-->
| C=20 | H=25 | N=1 | O=2 | S=2
| molecular_weight = 375.55 g/mol
| SMILES = O=C(O)[C@H]1CN(CCC1)CC/C=C(/c2sccc2C)c3sccc3C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PBJUNZJWGZTSKL-MRXNPFEDSA-N
}}

'''Tiagabine''' (trade name '''Gabitril''') is an [[anticonvulsant]] [[medication]] used in the treatment of [[epilepsy]] that is produced by [[Cephalon]]. The drug is also used [[off-label]] in the treatment of [[anxiety disorder]]s and [[panic disorder]].

==Medical uses==
Tiagabine is approved by U.S. [[Food and Drug Administration]] (FDA) as an adjunctive treatment for partial [[seizures]] in individuals of age 12 and up. It may also be prescribed off-label by physicians to treat anxiety disorders and panic disorder as well as [[neuropathic pain]] (including [[fibromyalgia]]). For anxiety and neuropathic pain, tiagabine is used primarily to augment other treatments. Tiagabine may be used alongside [[selective serotonin reuptake inhibitor]]s, [[Serotonin–norepinephrine reuptake inhibitor|serotonin-norepinephrine reuptake inhibitor]]s, or [[benzodiazepine]]s for anxiety, or [[antidepressant]]s, [[gabapentin]], other anticonvulsants, or [[opioid]]s for neuropathic pain.<ref name="Stahl">Stahl, S. Stahl's Essential Psychopharmacology: Prescriber's Guide. Cambridge University Press: New York, NY. 2009. pp. 523-526</ref>

==Side effects==
The most common [[side effect]] of tiagabine is [[dizziness]].<ref name="Leppik1995">{{cite journal|last1=Leppik|first1=Ilo E.|title=Tiagabine: The Safety Landscape|journal=Epilepsia|volume=36|issue=s6|year=1995|pages=S10–S13|issn=0013-9580|doi=10.1111/j.1528-1157.1995.tb06009.x}}</ref> Other side effects that have been observed with a rate of statistical significance relative to [[placebo]] include [[asthenia]], [[somnolence]], [[wikt:nervousness|nervousness]], [[memory impairment]], [[tremor]], [[headache]], [[diarrhea]], and [[depression (mood)|depression]].<ref name="Leppik1995" /><ref name="EadieVajda2012">{{cite book|author1=M.J. Eadie|author2=F. Vajda|title=Antiepileptic Drugs: Pharmacology and Therapeutics|url=https://books.google.com/books?id=8iv6CAAAQBAJ&pg=PA459|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-60072-2|pages=459–}}</ref> Adverse effects such as [[confusion]], [[aphasia]] (difficulty speaking clearly)/[[stuttering]], and [[paresthesia]] (a tingling sensation in the body's extremities, particularly the hands and fingers) may occur at higher dosages of the drug (e.g., over 8&nbsp;mg/day).<ref name="Leppik1995" /> Tiagabine may induce [[seizures]] in those without [[epilepsy]], particularly if they are taking another drug which lowers the [[seizure threshold]].<ref name="Stahl" /> There may be an increased risk of [[psychosis]] with tiagabine treatment, although data is mixed and inconclusive.<ref name="LemkeWilliams2012" /><ref name="Aronson2009">{{cite book|author=J. K. Aronson|title=Meyler's Side Effects of Psychiatric Drugs|url=https://books.google.com/books?id=AmYFTSO8jCkC&pg=PA652|year=2009|publisher=Elsevier|isbn=978-0-444-53266-4|pages=652–}}</ref> Tiagabine can also reportedly interfere with visual [[color perception]].<ref name="LemkeWilliams2012" />

==Overdose==
Tiagabine [[overdose]] can produce neurological symptoms such as [[lethargy]], single or multiple [[seizure]]s, [[status epilepticus]], [[coma]], [[confusion]], [[Psychomotor agitation|agitation]], [[tremor]]s, [[dizziness]], [[dystonia]]s/[[abnormal posturing]], and [[hallucination]]s, as well as [[respiratory depression]], [[tachycardia]], [[hypertension]], and [[hypotension]].<ref name="SpillerWinter2009">{{cite journal|last1=Spiller|first1=Henry A.|last2=Winter|first2=Mark L.|last3=Ryan|first3=Mark|last4=Krenzelok|first4=Edward P.|last5=Anderson|first5=Debra L.|last6=Thompson|first6=Michael|last7=Kumar|first7=Suparna|title=Retrospective Evaluation of Tiagabine Overdose|journal=Clinical Toxicology|volume=43|issue=7|year=2009|pages=855–859|issn=1556-3650|doi=10.1080/15563650500357529}}</ref> Overdose may be fatal especially if the victim presents with severe respiratory depression and/or unresponsiveness.<ref name="SpillerWinter2009" />

==Pharmacology==
Tiagabine increases the level of [[gamma-Aminobutyric acid|γ-aminobutyric acid]] (GABA), the major inhibitory [[neurotransmitter]] in the [[central nervous system]], by blocking the [[GABA transporter 1]] (GAT-1), and hence is classified as a [[GABA reuptake inhibitor]] (GRI).<ref name="Brodie1995" /><ref name="pmid16420077">{{cite journal |vauthors=Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K | title = The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study | journal = The Journal of Clinical Psychiatry | volume = 66 | issue = 11 | pages = 1401–8 | date = November 2005 | pmid = 16420077 | doi = 10.4088/JCP.v66n1109 | url = http://article.psychiatrist.com/?ContentType=START&ID=10001907 }}</ref>

==History==
Tiagabine was discovered at [[Novo Nordisk]] in Denmark in 1988 by a team of [[Medicinal chemistry|medicinal chemists]] and [[Pharmacology|pharmacologists]] under the general direction of Claus Bræstrup.<ref name="Andersen_1993">{{cite journal |vauthors=Andersen KE, Braestrup C, Grønwald FC, Jørgensen AS, Nielsen EB, Sonnewald U, Sørensen PO, Suzdak PD, Knutsen LJ | title = The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate | journal = J. Med. Chem. | volume = 36 | issue = 12 | pages = 1716–25 | year = 1993 | pmid = 8510100 | doi = 10.1021/jm00064a005 }}</ref>  The drug was co-developed with [[Abbott Laboratories]], in a 40/60 cost sharing deal, with Abbott paying a premium for licensing the IP from the Danish company.{{citation needed|date=October 2014}}

Abbott did initially embrace the drug enthusiastically after its U.S. launch in 1998, and provided further clinical studies with the goal of gaining FDA approval for monotherapy in epilepsy.  However, the senior management at Abbott drew back after realizing that the original deal with Novo would limit the company's financial gain from a monotherapy approval. After a period of co-promotion, Cephalon licensed tiagabine from Abbott/Novo and now is the exclusive producer.{{citation needed|date=October 2014}}

U.S. patents on tiagabine listed in the [[Approved Drug Products with Therapeutic Equivalence Evaluations|Orange Book]] expired in April 2016.<ref>Orange Book [http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020646&TABLE1=OB_Rx index page].  Accessed March 22, 2016</ref>

==See also==
* [[CI-966]]
* [[Deramciclane]]
* [[Nipecotic acid]]
* [[SKF-89976A]]

==References==
{{Reflist|2}}

==External links==
* [https://web.archive.org/web/20060126205608/http://www.gabitril.com:80/physicians/home/default.asp Gabitril](manufacturer's website)

{{Anticonvulsants}}
{{Anxiolytics}}
{{GABA metabolism and transport modulators}}

[[Category:Anticonvulsants]]
[[Category:Anxiolytics]]
[[Category:Carboxylic acids]]
[[Category:GABA reuptake inhibitors]]
[[Category:Piperidines]]
[[Category:Thiophenes]]